EN DE
Watch BioInvent International AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BioInvent International AB (BINV) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of BioInvent International AB stock SEK 7.47, price SEK 2.49, upside +200.0%, quality 51 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0015244520

BI BioInvent International AB logo Thin data Nov 6, 2026

BioInvent International AB

BINV · ST
Undervalued, but in a downtrend

The stock costs 67% less than our calculation considers fair.

Fair value kr 7.47 · Strongly undervalued
Ranks above peers (6/9)
Even on cautious assumptions the value is 98% above the price (kr 4.94).
Quality 51/100
Weak Growth (revenue 3y −11.4 %/yr in SEK)
Loss-making · -147.0% net margin (FY2025)
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Watch BioInvent International AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 50.80 kr 2.49 Fair Value kr 7.47 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range kr 2.49 – kr 50.80 · fair‑value band kr 4.94 – kr 9.35 · the kr 2.49 price screens below the kr 7.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow BioInvent International in your weekly email

Every Wednesday you see whether BioInvent International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally.

Show moreShow less

The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors.

It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Stock analysis

BioInvent International AB (BINV) currently trades at kr 2.49, while our model-based Fair Value estimate is kr 7.47, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 4.94 (bear) to kr 9.35 (bull), the price of kr 2.49 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

BioInvent International AB reported revenue of 226M SEK in FY2025 versus 19.4M SEK in FY2021, a compound +84.9%/yr. Reported net income was −333M SEK in FY2025.

Key figures

Market cap 236M SEK (≈ $23.9M) Micro · P/S ratio 5.90 · EPS (TTM) kr −7.40 · Net margin −147% · Return on equity −110% · Return on assets (EBIT) −29.7% (5-year average) · Operating margin −1,116% · Revenue growth (YoY) +225%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 93% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 200%, BINV screens cheaper than that median.

Fair Value models

Bear kr 4.94 Fair Value kr 7.47 Bull kr 9.35
Price kr 2.49 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 5.26 kr 7.96 kr 9.96 52
All 1 models by family
Asset-Based
NCAV (Graham) kr 5.26 kr 7.96 kr 9.96 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+406.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Start year 2020 (pandemic)
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−51.2% (2020) → −155.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BINV, get fair value alerts →

Compare BioInvent International AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 6/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside +200.0% · Top 25%
Profitability
Return on assets −49.6% · Bottom 25%
Net margin (12 months) −147.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 225.0% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.42× · Cheapest 25%
P/S (12 months) 5.90× · Cheaper than median
PEG 0.27× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs BINV
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs BINV
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs BINV
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs BINV
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs BINV
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs BINV
argenx SE ARGX $927.21 $908.40 −2% vs BINV
CSL Limited CSL A$200.77 A$183.04 −9% vs BINV
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs BINV
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs BINV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioInvent International AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BioInvent International AB Fair Value". https://www.fairvalue-calculator.com/stock/BINV

Frequently asked questions

Is BioInvent International AB (BINV) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of kr 7.47 versus a price of kr 2.49, about +200% upside (undervalued).
What is the fair value of BINV?
Our model-based fair value for BioInvent International AB is kr 7.47 (as of Nov 6, 2026), built from audited fundamentals. The current price: kr 2.49.
What is the quality score of BINV?
BioInvent International AB has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioInvent International AB (BINV)?
Our model-based price target is the fair value of kr 7.47 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario kr 4.94, optimistic scenario kr 9.35. It is a calculation from audited fundamentals, not an analyst target.
What is the BioInvent International AB stock forecast for 2026?
Our models put fair value at kr 7.47, about +200% upside versus a price of kr 2.49 (undervalued). Cautious scenario kr 4.94, optimistic scenario kr 9.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of BioInvent International AB (BINV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioInvent International AB it is kr 7.47 per share (as of Nov 6, 2026), against a price of kr 2.49. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is BioInvent International AB stock overvalued or undervalued in 2026?
As of Nov 6, 2026, BINV trades below its calculated fair value: price kr 2.49, fair value kr 7.47, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BINV?
No. The price is what the market pays today (kr 2.49); the fair value is what the company's own numbers justify (kr 7.47). For BioInvent International AB the two are kr 4.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioInvent International AB worth?
The market values BioInvent International AB at about 236M SEK (market capitalisation, as of Nov 6, 2026). Per share that is kr 2.49; our models calculate a fair value of kr 7.47 per share.
What do the bullish and bearish scenarios say about BINV?
Our models span a range for BioInvent International AB: cautious scenario kr 4.94, base kr 7.47, optimistic kr 9.35 per share (as of Nov 6, 2026, price kr 2.49). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BINV?
The PEG ratio of BioInvent International AB is 0.27 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of BioInvent International AB (BINV)?
Balance-sheet figures for BioInvent International AB (as of Nov 6, 2026): return on equity −110.2%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is BINV from its 52-week high?
BioInvent International AB trades at kr 2.49, about 93% below its 52-week high of kr 33.75 and at the low of kr 2.49 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 7.47 is for.
Which stocks are comparable to BioInvent International AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioInvent International AB stock attractive at the current price?
The data as of Nov 6, 2026: price kr 2.49, calculated fair value kr 7.47 (+200%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BINV calculated?
We run BioInvent International AB through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 7.47 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BioInvent International AB currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioInvent International AB (BINV)?
The closing price on Nov 6, 2026 was kr 2.49. Our model-based fair value is kr 7.47, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioInvent International AB right now?
The price is below even our cautious bear case (kr 4.94). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (kr 4.94 to kr 9.35) leaves room in how you read the outcome.

Key figures of BioInvent International AB

How large is the market capitalisation of BioInvent International AB (BINV)?
The market capitalisation of BioInvent International AB is 236M SEK (≈ $23.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioInvent International AB (BINV)?
The price-to-sales ratio of BioInvent International AB is 5.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioInvent International AB (BINV)?
Earnings per share at BioInvent International AB are kr −7.40. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioInvent International AB (BINV)?
The net margin of BioInvent International AB is −147% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioInvent International AB (BINV)?
The return on equity (ROE) of BioInvent International AB is −110% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioInvent International AB (BINV)?
On an EBIT basis the return on assets of BioInvent International AB is −29.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioInvent International AB (BINV)?
The operating margin of BioInvent International AB is −1,116% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioInvent International AB (BINV)?
Revenue at BioInvent International AB is growing +225% versus a year earlier (3y avg −11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BioInvent International AB (BINV) generate?
The free cash flow of BioInvent International AB is −255M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BioInvent International AB (BINV) hold?
BioInvent International AB holds more cash than debt, 346M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BioInvent International AB in the live analysis

One click puts BioInvent International AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.